Physician profile
Michael D Keller
NPI 1174724405
$8,565.24
in general payments reported to CMS, 2019-2025
8 companies · $475 in 2025
The $475 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,072 · 2023: $108 · 2024: $2,911 · 2025: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,260 · Honoraria: $600 · Food and Beverage: $555 · Education: $77.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,260.00 |
| Honoraria | $600.00 |
| Food and Beverage | $554.90 |
| Education | $77.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $5,072.35 | 2019 | |
| Chiesi USA, INC. | $2,560.00 | 2024-2025 | Revcovi |
| Sobi, INC | $404.24 | 2023-2025 | |
| Csl Behring | $300.00 | 2024 | Hizentra |
| Amgen INC. | $77.62 | 2024 | Actimmune |
| Incyte Corporation | $68.10 | 2024 | |
| Horizon Therapeutics Plc | $44.88 | 2023 | Actimmune |
| Mindray Ds USA, INC. | $38.05 | 2024 | Te X, Te7 Max |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Keller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.